Massachusetts Financial Services Co. MA grew its stake in shares of CG Oncology, Inc. (NASDAQ:CGON – Free Report) by 2.7% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 266,787 shares of the company’s stock after buying an additional 6,899 shares during the period. Massachusetts Financial Services Co. MA owned 0.40% of CG Oncology worth $8,422,000 at the end of the most recent reporting period.
A number of other institutional investors also recently made changes to their positions in CGON. BNP Paribas Financial Markets acquired a new position in shares of CG Oncology in the first quarter valued at approximately $492,000. Capstone Investment Advisors LLC purchased a new position in shares of CG Oncology during the 1st quarter worth $806,000. TimesSquare Capital Management LLC acquired a new stake in shares of CG Oncology during the first quarter worth $9,837,000. Vanguard Group Inc. purchased a new stake in shares of CG Oncology in the first quarter valued at $97,678,000. Finally, Ameritas Investment Partners Inc. acquired a new position in CG Oncology in the first quarter valued at $102,000. 26.56% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In other CG Oncology news, Director Hong Fang Song sold 650,455 shares of the stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $35.36, for a total value of $23,000,088.80. Following the completion of the sale, the director now owns 586,982 shares of the company’s stock, valued at $20,755,683.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Analyst Ratings Changes
Check Out Our Latest Stock Analysis on CGON
CG Oncology Price Performance
Shares of CGON stock opened at $39.00 on Friday. The company’s fifty day simple moving average is $35.29 and its 200-day simple moving average is $35.32. CG Oncology, Inc. has a 52 week low of $25.77 and a 52 week high of $50.23.
CG Oncology (NASDAQ:CGON – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.14. The company had revenue of $0.11 million during the quarter. As a group, research analysts forecast that CG Oncology, Inc. will post -1.47 earnings per share for the current year.
CG Oncology Profile
CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
See Also
- Five stocks we like better than CG Oncology
- The Risks of Owning Bonds
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- What is the Dogs of the Dow Strategy? Overview and Examples
- MarketBeat Week in Review – 9/16 – 9/20
- What is the S&P 500 and How It is Distinct from Other Indexes
- Don’t Miss These 3 Retail Stocks for Fall Gains
Want to see what other hedge funds are holding CGON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CG Oncology, Inc. (NASDAQ:CGON – Free Report).
Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.